Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

Molecular Cancer Therapeutics

Volumn 5, Issue 1, 2006, Pages 160-169

  Koblish, Holly K ^a   Zhao, Shuyuan ^a   Franks, Carol F ^a   Donatelli, Robert R ^a   Tominovich, Rose M ^a   LaFrance, Louis V ^a,b   Leonard, Kristi A ^a   Gushue, Joan M ^a,c   Parks, Daniel J ^a   Calvo, Raul R ^a   Milkiewicz, Karen L ^a,d   Marugán, Juan José ^a   Raboisson, Pierre ^a,e   Cummings, Maxwell D ^a   Grasberger, Bruce L ^a   Johnson, Dana L ^a   Lu, Tianbao ^a   Molloy, Christopher J ^a   Maroney, Anna C ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b GLAXOSMITHKLINE   (United States)

^c ICON CLINICAL RESEARCH   (United States)

^d CEPHALON INC   (United States)

^e Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; PROTEIN MDM2; PROTEIN P53; TDP 222669; TDP 521252; TDP 536356; TDP 665759; UNCLASSIFIED DRUG; MDM2 PROTEIN, HUMAN; MULTIPROTEIN COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL LINE; CELL PROLIFERATION; CELL STRAIN HEPG2; CHORIOCARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; DNA DAMAGE; DRUG DESIGN; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG STRUCTURE; FEMALE; GENE ACTIVITY; GENE CONTROL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MICROCALORIMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TUMOR CELL; TUMOR XENOGRAFT; UPREGULATION; XENOGRAFT; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; GENETICS; LIVER TUMOR; METABOLISM; MOUSE; MUTATION; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZODIAZEPINES; BENZODIAZEPINONES; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MULTIPROTEIN COMPLEXES; MUTATION; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644873086     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0199     Document Type: Article

References (66)

1. Jones SN, Sands AT, Hancock AR, et al. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci U S A 1996;93: 14106-11.
2. Keshelava N, Zuo JJ, Chen P, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001;61:6185-93.
3. Johnston JB, Daeninck P, Verburg L, et al. p53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997;26:435-49.
4. Buttitta F, Marchetti A, Gadducci A, et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997;75:230-5.
5. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-82.
6. Coukos G, Rubin SC. Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet Gynecol 1998;91:783-92.
7. Harada T, Ogura S, Yamazaki K, et al. Predictive value of expression of p53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 2003;94: 394-9.
8. Yamazaki Y, Chiba I, Hirai A, et al. Radioresistance in oral squamous cell carcinoma with p53 DNA contact mutation. Am J Clin Oncol 2003;26: e124-9.
9. Beroud C, Soussi T. p53 gene mutation: software and database. Nucleic Acids Res 1998;26:200-4.
10. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-9.
11. Chene P. Targeting p53 in cancer. Curr Med Chem Anti-Canc Agents 2001;1:151-61.
12. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003;3:102-9.
13. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
14. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995;378: 206-8.
15. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995;378:203-6.
16. Bottger A, Bottger V, Garcia-Echeverria C, et al. Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997;269:744-56.
17. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7.
18. Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M, Tominaga T. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 1998;89:221-7.
19. Zhou M, Gu L, Abshire TC, et al. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 2000;14:61-7.
20. Ikeguchi M, Ueda T, Fukuda K, Yamaguchi K, Tsujitani S, Kaibara N. Expression of the murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am J Clin Oncol 2002;25:454-9.
21. Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci U S A 1998;95:195-200.
22. Chen L, Lu W, Agrawal S, Zhou W, Zhang R, Chen J. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol Med 1999;5:21-34.
23. Tortora G, Caputo R, Damiano V, et al. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int J Cancer 2000;88:804-9.
24. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997;7:860-9.
25. Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 2001;7:3613-24.
26. Pearson S, Jia H, Kandachi K. China approves first gene therapy. Nat Biotechnol 2004;22:3-4.
27. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002;8:S38-42.
28. Grasberger BL, Lu T, Schubert C, et al. Discovery and cocrystal structure of benzodiazepinedione Hdm2 antagonists that activate p53 in cells. J Med Chem 2005;48:909-12.
29. Parant J, Chavez-Reyes A, Little NA, et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 2001;29: 92-5.
30. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
31. Pantoliano MW, Petrella EC, Kwasnoski JD, et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 2001;6:429-40.
32. Parks DJ, Lafrance LV, Calvo RR, et al. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg Med Chem Lett 2005;15:765-70.
33. Wang H, Zeng X, Oliver P, et al. MDM2 oncogene as a target for cancer therapy: an antisense approach. Int J Oncol 1999;15:653-60.
34. Milczarek GJ, Martinez J, Bowden GT. p53 Phosphorylation: biochemical and functional consequences. Life Sci 1997;60:1-11.
35. Meek DW. Post-translational modification of p53. Semin Cancer Biol 1994;5:203-10.
36. Thompson T, Tovar C, Yang H, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004;279:53015-22.
37. Lee TK, Lau TC, Ng IO. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 2002; 49:78-86.
38. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
39. Slee EA, O'Connor DJ, Lu X. To die or not to die: how does p53 decide? Oncogene 2004;23:2809-18.
40. Flatt PM, Polyak K, Tang LJ, et al. p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Lett 2000;156:63-72.
41. Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci U S A 2002;99:95-100.
42. 55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 2004;23:3580-8.
43. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002;62:7316-27.
44. Bartel F, Harris LC, Wurl P, Taubert H. MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides. Mol Cancer Res 2004;2:29-35.
45. Kawabe S, Munshi A, Zumstein LA, Wilson DR, Roth JA, Meyn RE. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts. Int J Radiat Biol 2001;77:185-94.
46. Prasad G, Wang H, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res 2002;22:107-16.
47. Wang H, Yu D, Agrawal S, Zhang R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 2003;54:194-205.
48. Zhang Z, Wang H, Prasad G, et al. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 2004;10:1263-73.
49. Cristofanilli M, Khrisnamurthy S, Guerra L, et al. Advexin® (Ad5CMV-p53) combined with docetaxel (T) and doxorubicin (D) as induction chemotherapy (IC): efficacy of a novel gene-therapy approach for patients with locally advanced breast cancer (LABC). 27th Annual San Antonio Breast Cancer Symposium; San Antonio TX; 2004.
50. Haapajarvi T, Pitkanen K, Laiho M. Human melanoma cell line UV responses show independency of p53 function. Cell Growth Differ 1999; 10:163-71.
51. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
52. Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 1999;431:199-209.
53. Hainaut P. Tumor-specific mutations in p53: the acid test. Nat Med 2002;8:21-3.
54. Zeimet A, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 2003;4:415-22.
55. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996;2:912-7.
56. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A 1998;95: 15608-12.
57. 1 arrest that is suppressed by MDM2. J Biol Chem 2000;275:31883-90.
58. Reinke V, Lozano G. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene 1997;15:1527-34.
59. Ha L, Ceryak S, Patierno SR. Chromium (VI) activates ataxia telangiectasia mutated (ATM) protein. Requirement of ATM for both apoptosis and recovery from terminal growth arrest. J Biol Chem 2003; 278:17885-94.
60. Wolf BB, Schuler M, Echeverri F, Green DR. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 1999;274:30651-6.
61. Isaacs JS, Saito S, Neckers LM. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma. J Biol Chem 2001;276: 18497-506.
62. Fan S, Smith ML, Rivet DJ, II, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55:1649-54.
63. L. Mol Cancer Ther 2005;4:1096-104.
64. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303: 844-8.
65. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10:1321-8.
66. Krajewski M, Ozdowy P, D'Silva L, Rothweiler U, Holak TA. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med 2005;11:1135-6.